Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA To Address Companion Dx Development In Separate Guidances

This article was originally published in The Gray Sheet

Executive Summary

FDA hopes to issue draft guidance on companion diagnostics this year, but the document will focus only on the process for adding a diagnostic to an already marketed drug, not simultaneous drug/diagnostic development, according to an agency official.

You may also be interested in...



More Rx, Dx Firms Join Forces On Companion Diagnostics, But Obstacles To European Market Remain

A "highly regionalized payer environment, with variable health technology assessment requirements and an associated reimbursement time lag" is to blame for much of the problem, French industry exec says.

More Rx, Dx Firms Join Forces On Companion Diagnostics, But Obstacles To European Market Remain

While increasing collaborations between drug and diagnostics companies bode well for the future of companion diagnostics, significant reimbursement and regulatory barriers in Europe continue to vex product developers.

More Rx, Dx Firms Join Forces On Companion Diagnostics, But Obstacles To European Market Remain

While increasing collaborations between drug and diagnostics companies bode well for the future of companion diagnostics, significant reimbursement and regulatory barriers in Europe continue to vex product developers.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT029591

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel